NASDAQ:INFI

Infinity Pharmaceuticals Stock Forecast, Price & News

$2.66
-0.27 (-9.22 %)
(As of 08/3/2021 12:00 AM ET)
Add
Compare
Today's Range
$2.43
$2.90
50-Day Range
$1.52
$3.47
52-Week Range
$0.91
$5.98
Volume15.41 million shs
Average Volume4.76 million shs
Market Capitalization$236.00 million
P/E RatioN/A
Dividend YieldN/A
Beta2.12
30 days | 90 days | 365 days | Advanced Chart
Receive INFI News and Ratings via Email

Sign-up to receive the latest news and ratings for Infinity Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Infinity Pharmaceuticals logo

About Infinity Pharmaceuticals

Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 1/1b clinical trials for the treatment of triple negative breast cancer, solid tumors, and ovarian cancer. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Cambridge, Massachusetts.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.81 out of 5 stars

Medical Sector

758th out of 1,309 stocks

Pharmaceutical Preparations Industry

374th out of 646 stocks

Analyst Opinion: 3.5Community Rank: 3.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Infinity Pharmaceuticals (NASDAQ:INFI) Frequently Asked Questions

Is Infinity Pharmaceuticals a buy right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Infinity Pharmaceuticals in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Infinity Pharmaceuticals stock.
View analyst ratings for Infinity Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Infinity Pharmaceuticals?

Wall Street analysts have given Infinity Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Infinity Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Infinity Pharmaceuticals?

Infinity Pharmaceuticals saw a decline in short interest during the month of July. As of July 15th, there was short interest totaling 4,430,000 shares, a decline of 19.2% from the June 30th total of 5,480,000 shares. Based on an average daily trading volume, of 1,850,000 shares, the short-interest ratio is currently 2.4 days. Approximately 5.1% of the company's shares are sold short.
View Infinity Pharmaceuticals' Short Interest
.

When is Infinity Pharmaceuticals' next earnings date?

Infinity Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, November 8th 2021.
View our earnings forecast for Infinity Pharmaceuticals
.

How were Infinity Pharmaceuticals' earnings last quarter?

Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) posted its quarterly earnings data on Tuesday, July, 27th. The biotechnology company reported ($0.13) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.14) by $0.01. Infinity Pharmaceuticals had a negative trailing twelve-month return on equity of 304.81% and a negative net margin of 2,251.75%.
View Infinity Pharmaceuticals' earnings history
.

How has Infinity Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Infinity Pharmaceuticals' stock was trading at $1.01 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, INFI shares have increased by 163.4% and is now trading at $2.66.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for INFI?

8 brokerages have issued 1-year price objectives for Infinity Pharmaceuticals' stock. Their forecasts range from $4.00 to $14.00. On average, they expect Infinity Pharmaceuticals' stock price to reach $9.63 in the next twelve months. This suggests a possible upside of 261.8% from the stock's current price.
View analysts' price targets for Infinity Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Infinity Pharmaceuticals' key executives?

Infinity Pharmaceuticals' management team includes the following people:
  • Ms. Adelene Q. Perkins, Chairman & CEO (Age 61, Pay $1.15M)
  • Dr. Lawrence E. Bloch, Pres & Treasurer (Age 55, Pay $742.45k)
  • Mr. Seth A. Tasker, Sr. VP, Chief Bus. Officer & Sec. (Age 42, Pay $549.61k)
  • Ms. Melissa Hackel, VP of Fin.
  • Dr. Jeffery L. Kutok, Chairman of Scientific Advisory Board (Age 54)
  • Ms. Rossitza Alargova Ph.D., Head of Pharmaceutical Devel.
  • Dr. Brian Schwartz, Consulting Chief Physician (Age 59)
  • Jayne Kauffman, Sr. Exec. Coordinator

What is Adelene Q. Perkins' approval rating as Infinity Pharmaceuticals' CEO?

10 employees have rated Infinity Pharmaceuticals CEO Adelene Q. Perkins on Glassdoor.com. Adelene Q. Perkins has an approval rating of 100% among Infinity Pharmaceuticals' employees. This puts Adelene Q. Perkins in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Infinity Pharmaceuticals' key competitors?

What other stocks do shareholders of Infinity Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Infinity Pharmaceuticals investors own include Continental Resources (CLR), Rex Energy (REXX), Aerie Pharmaceuticals (AERI), Gilead Sciences (GILD), OPKO Health (OPK), AVEO Pharmaceuticals (AVEO), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), Novavax (NVAX) and Celldex Therapeutics (CLDX).

What is Infinity Pharmaceuticals' stock symbol?

Infinity Pharmaceuticals trades on the NASDAQ under the ticker symbol "INFI."

Who are Infinity Pharmaceuticals' major shareholders?

Infinity Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include New York State Common Retirement Fund (0.08%), Alliancebernstein L.P. (0.02%) and Lindbrook Capital LLC (0.01%).
View institutional ownership trends for Infinity Pharmaceuticals
.

Which institutional investors are buying Infinity Pharmaceuticals stock?

INFI stock was purchased by a variety of institutional investors in the last quarter, including New York State Common Retirement Fund, Alliancebernstein L.P., and Lindbrook Capital LLC.
View insider buying and selling activity for Infinity Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Infinity Pharmaceuticals?

Shares of INFI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Infinity Pharmaceuticals' stock price today?

One share of INFI stock can currently be purchased for approximately $2.66.

How much money does Infinity Pharmaceuticals make?

Infinity Pharmaceuticals has a market capitalization of $236.00 million and generates $1.72 million in revenue each year. The biotechnology company earns $-40,490,000.00 in net income (profit) each year or ($0.68) on an earnings per share basis.

How many employees does Infinity Pharmaceuticals have?

Infinity Pharmaceuticals employs 23 workers across the globe.

What is Infinity Pharmaceuticals' official website?

The official website for Infinity Pharmaceuticals is www.infi.com.

Where are Infinity Pharmaceuticals' headquarters?

Infinity Pharmaceuticals is headquartered at 1100 MASSACHUSETTS AVENUE FLOOR 4, CAMBRIDGE MA, 02138.

How can I contact Infinity Pharmaceuticals?

Infinity Pharmaceuticals' mailing address is 1100 MASSACHUSETTS AVENUE FLOOR 4, CAMBRIDGE MA, 02138. The biotechnology company can be reached via phone at 617-453-1000 or via email at [email protected]


This page was last updated on 8/3/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.